Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre
Lukas M, Malickova K, Kolar M, Bortlik M, Vasatko M, Machkova N, Hruba V, Duricova D, Lukas M. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre. J Crohns Colitis. 2020 Jul 30;14(7):915-919. doi:10.1093/ecco-jcc/jjaa001. PMID: 31905382
Další publikace
Vliv pandemie COVID-19 na endoskopickou praxi v České republice – dotazníková
studie
přejít na článek
studie
Development and Validation of a Patient-reported Score to Screen for Mucosal Inflammation in Inflammatory Bowel
Disease
přejít na článek
Disease
Iron substitution in sideropenia or sideropenic anemia in patients with IBD with heme iron containing
preparation
přejít na článek
preparation
Practical guidelines on endoscopic treatment for Crohn’s disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease
Group
přejít na článek
Group
Vedolizumab as Induction and Maintenance Therapy for Crohn’s Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist
Therapy
přejít na článek
Therapy
Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International
Meeting
přejít na článek
Meeting
Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative
Colitis
přejít na článek
Colitis
Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based
study
přejít na článek
study
Pentane and other volatile organic compounds, including carboxylic acids, in the exhaled breath of patients with Crohn’s disease and ulcerative
colitis
přejít na článek
colitis
Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative
Colitis
přejít na článek
Colitis
Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort-An ECCO-EpiCom
Study
přejít na článek
Study